NextPharma has successfully completed an FDA inspection at its Braine-l’Alleud site, near Brussels in Belgium, a facility for aseptic production and packaging, including the manufacture of cytotoxic products. The inspection was in support of a patented lyophilized medicinal product for cancer treatment manufactured in the company’s dedicated cytotoxic facility. The main part of the inspection paid specific attention to NextPharma’s Quality Management System and compliance with FDA GMP, in add...